Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed outcomes for some malignancies.(1) Tumor complexity and heterogeneity suggest that the “precision medicine” paradigm of cancer therapy requires treatment to be per...

Descripción completa

Detalles Bibliográficos
Autores principales: Sicklick, Jason K., Kato, Shumei, Okamura, Ryosuke, Schwaederle, Maria, Hahn, Michael E., Williams, Casey B., De, Pradip, Krie, Amy, Piccioni, David E., Miller, Vincent A., Ross, Jeffrey S., Benson, Adam, Webster, Jennifer, Stephens, Philip J., Lee, J. Jack, Fanta, Paul T., Lippman, Scott M., Leyland-Jones, Brian, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553618/
https://www.ncbi.nlm.nih.gov/pubmed/31011206
http://dx.doi.org/10.1038/s41591-019-0407-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553618/
https://www.ncbi.nlm.nih.gov/pubmed/31011206
http://dx.doi.org/10.1038/s41591-019-0407-5

Ejemplares similares